Intercept Stock Analysis

ICPT -  USA Stock  

USD 14.44  1.06  6.84%

The newest Intercept Pharmaceuticals price drop may raise some interest from private investors. The stock closed today at a share price of 14.44 on 708,340 in trading volume. The company directors and management were unable to exploit market volatilities in December. However, diversifying your overall positions with Intercept Pharmaceuticals can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.02. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Intercept Pharmaceuticals partners.
Please see Risk vs Return Analysis.

Intercept Stock Analysis 

 
Refresh
The Intercept Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Intercept Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Intercept Stock analysis module also helps to analyze the Intercept Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Intercept Stock Analysis Notes

About 18.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. Intercept Pharmaceuticals recorded a loss per share of 3.28. The entity had not issued any dividends in recent years. Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 498 people. To learn more about Intercept Pharmaceuticals call Mark Pruzanski at 646 747-1000 or check out www.interceptpharma.com.

Intercept Pharmaceuticals Quarterly Cost of Revenue

658,000Share

Intercept Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intercept Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intercept Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Intercept Pharmaceuticals generated a negative expected return over the last 90 days
Intercept Pharmaceuticals has high historical volatility and very poor performance
Intercept Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 354.33 M. Net Loss for the year was (107.29 M) with profit before overhead, payroll, taxes, and interest of 307.37 M.
Intercept Pharmaceuticals currently holds about 420.13 M in cash with (61.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.22.
Over 79.0% of the company shares are owned by institutional investors
Latest headline from www.digitaljournal.com: Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule - Digital Journal

Intercept Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Intercept Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intercept Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Intercept Largest EPS Surprises

Earnings surprises can significantly impact Intercept Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-05-14
2013-03-31-0.44-0.62-0.1840 
2021-05-06
2021-03-31-1.4904-1.220.270418 
2013-08-13
2013-06-30-0.51-0.79-0.2854 
View All Earnings Estimates

Intercept Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Intercept Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Intercept Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Intercept Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
20th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
10th of December 2021
Unclassified Corporate Event
View
9th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
3rd of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
22nd of October 2021
Submission of Matters to a Vote of Security Holders
View
21st of September 2021
Unclassified Corporate Event
View
16th of September 2021
Unclassified Corporate Event
View

Intercept Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 454.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intercept Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Intercept Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Intercept Profitablity

Intercept Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Intercept Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Intercept Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Intercept Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Intercept Pharmaceuticals' profitability requires more research than a typical breakdown of Intercept Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (30.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (20.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.21.
Last ReportedProjected for 2022
Return on Investment(42.59) (45.95) 
Return on Average Assets(0.51) (0.55) 
Return on Average Equity 3.08  3.32 
Return on Invested Capital(0.22) (0.22) 
Return on Sales(0.83) (0.90) 

Management Efficiency

The entity has return on total asset (ROA) of (8.33) % which means that it has lost $8.33 on every $100 spent on asset. This is way below average. Intercept Pharmaceuticals management efficiency ratios could be used to measure how well intercept pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to gain to 3.32 in 2022, whereas Return on Investment is likely to drop (45.95)  in 2022. Total Liabilities is likely to gain to about 927.3 M in 2022. Current Liabilities is likely to gain to about 222.2 M in 2022
Last ReportedProjected for 2022
Book Value per Share(4.55) (4.67) 
Enterprise Value over EBIT(6.90) (7.44) 
Enterprise Value over EBITDA(6.96) (7.51) 
Price to Book Value(5.62) (5.77) 
Tangible Assets Book Value per Share 20.25  21.12 
Enterprise Value1.5 B2.2 B
Tangible Asset Value667.6 M598 M

Technical Drivers

As of the 27th of January, Intercept Pharmaceuticals retains the risk adjusted performance of (0.08), and Market Risk Adjusted Performance of (0.23). Intercept Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Intercept Pharmaceuticals, which can be compared to its competitors. Please check out Intercept Pharmaceuticals information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Intercept Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 14.44 per share. Given that Intercept Pharmaceuticals has jensen alpha of (0.30), we strongly advise you to confirm Intercept Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.

Intercept Pharmaceuticals Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Triangular Moving Average shows Intercept Pharmaceuticals double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Intercept Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intercept Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intercept Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intercept Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ball Bryan over a week ago via Macroaxis 
Payment of 2455 shares by Ball Bryan of Intercept Pharmaceuticals subject to Rule 16b-3
Mark Pruzanski over a month ago via Macroaxis 
Payment of 3817 shares by Mark Pruzanski of Intercept Pharmaceuticals subject to Rule 16b-3
Richardson Linda M over two months ago via Macroaxis 
Payment of 171 shares by Richardson Linda M of Intercept Pharmaceuticals subject to Rule 16b-3
Gail Cawkwell over two months ago via Macroaxis 
Payment of 319 shares by Gail Cawkwell of Intercept Pharmaceuticals subject to Rule 16b-3
Mark Pruzanski over two months ago via Macroaxis 
Payment of 3817 shares by Mark Pruzanski of Intercept Pharmaceuticals subject to Rule 16b-3
Defrancesco Lisa over three months ago via Macroaxis 
Payment of 204 shares by Defrancesco Lisa of Intercept Pharmaceuticals subject to Rule 16b-3
Mark Pruzanski over three months ago via Macroaxis 
Payment of 3816 shares by Mark Pruzanski of Intercept Pharmaceuticals subject to Rule 16b-3
Venezia Rocco over three months ago via Macroaxis 
Payment of 524 shares by Venezia Rocco of Intercept Pharmaceuticals subject to Rule 16b-3
Mark Pruzanski over three months ago via Macroaxis 
Payment of 3817 shares by Mark Pruzanski of Intercept Pharmaceuticals subject to Rule 16b-3
Mark Pruzanski over three months ago via Macroaxis 
Acquisition by Mark Pruzanski of 6138 shares of Intercept Pharmaceuticals subject to Rule 16b-3
Richardson Linda M over three months ago via Macroaxis 
Payment of 171 shares by Richardson Linda M of Intercept Pharmaceuticals subject to Rule 16b-3
Mark Pruzanski over three months ago via Macroaxis 
Payment of 3817 shares by Mark Pruzanski of Intercept Pharmaceuticals subject to Rule 16b-3

Intercept Pharmaceuticals Predictive Daily Indicators

Intercept Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intercept Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Intercept Pharmaceuticals Forecast Models

Intercept Pharmaceuticals time-series forecasting models is one of many Intercept Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Intercept Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Intercept Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Intercept Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intercept shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Intercept Pharmaceuticals. By using and applying Intercept Stock analysis, traders can create a robust methodology for identifying Intercept entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(66.56) (71.81) 
EBITDA Margin(0.80) (0.86) 
Gross Margin 0.88  0.88 
Profit Margin(1.01) (1.09) 
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 498 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Intercept Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module
Please see Risk vs Return Analysis. Note that the Intercept Pharmaceuticals information on this page should be used as a complementary analysis to other Intercept Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Intercept Stock analysis

When running Intercept Pharmaceuticals price analysis, check to measure Intercept Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intercept Pharmaceuticals is operating at the current time. Most of Intercept Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Intercept Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intercept Pharmaceuticals' price. Additionally, you may evaluate how the addition of Intercept Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Intercept Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intercept Pharmaceuticals. If investors know Intercept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intercept Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intercept Pharmaceuticals is measured differently than its book value, which is the value of Intercept that is recorded on the company's balance sheet. Investors also form their own opinion of Intercept Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Intercept Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intercept Pharmaceuticals' market value can be influenced by many factors that don't directly affect Intercept Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intercept Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Intercept Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intercept Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.